APOE and type 2 diabetes mellitus: The effect of Arg‐II gene disruption on macrophage inflammation in vivo in a chronic inflammatory disease model, such as type II diabetes mellitus and atherogenesis, has not been investigated, although treatment of apolipoprotein E–deficient (ApoE−/−) mice with nonspecific arginase inhibitors has been shown to reduce atherosclerosis.25